The device was not returned for analysis.A review of the lot history record revealed no manufacturing nonconformities issued to the reported lot that would have contributed to this event.Additionally, a review of the complaint history identified no similar complaints reported from this lot.Based on available information, the cause of the reported slda was unable to be determined.The reported recurrent mr and heart failure were cascading events of the reported slda.The reported patient effects of heart failure and mitral regurgitation, as listed in the mitraclip system instructions for use, are known possible complications associated with mitraclip procedures.The reported serious injury/ illness/ impairment was a result of case-specific circumstances.There is no indication of a product quality issue with respect to manufacture, design, or labeling.
|
It was reported that on 23 february 2023, a mitraclip procedure was performed to treat functional mitral regurgitation (mr) grade 4.A xtw and a nt cliip were implanted successfully, reducing mr to trace.One year post procedure, a transesophageal echocardiogram (tee) follow up showed the nt detached from the anterior leaflet single leaflet device attachment (slda).Patient was not symptomatic but left ventricle function was less than 40% and mr was recurrent grade 3-4.No intervention was performed.Surgical intervention is considered.It was thought suboptimal medical management led further dilation of the valve resulting in the slda.
|